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Introduction
Human papillomaviruses (HPV) are ubiquitous agents 
with a double-stranded circular DNa consisting of 
around 8,000 base pairs. in terms of structure, HPVs 
consist of a capsid without an outer envelope consist-
ing of 72 pentagonal capsomers. the genome is able to 
code for two proteins (L1 and L2) which make up the 
outer envelope and which have a high immunogenic 
power and for 6 early proteins (E1, E2, E4, E5, E6 and 
E7) necessary for the replication of the viral DNa and 
for the assembly of the new virions in the infected cells. 
Phylogenetically HPVs are classified on the basis of 
the level of homology of the L1 capsid gene, which is 
genetically stable [1, 2].
based on a genomic homology of less than 90%, over 
100 types of HPV have been identified and are clas-
sified according to their oncogenic potential as high 
and low risk HPVs. the strains with a high oncogenic 
potential have a marked tendency to become integrated 
in the cell genome, leading to the interruption of the E2 
gene and the consequent loss of its control function on 
the expression of the E6 and E7 genes, whose products 
interact with cell cycle regulatory proteins (p53 and 
pRb) inhibiting the function and causing a high degree 
of genomic instability of the infected cells and loss of 
control of cell growth [3].
the causal role of high-risk HPVs in uterine cervical 
carcinoma has been confirmed from both a biological 
and epidemiological point of view [4].
in addition to cervical carcinoma, HPVs are responsi-
ble for other forms of anogenital (vulva, penis, vagina, 
anus) and oropharyngeal cancer [5].
the genotypes most frequently detected in all cervical 
tumours are HPV16, 18, 45 and 31; in particular HPV16 
and HPV18 cause over 70% of cervical tumours, while 
HPV16, HPV18, HPV45 and HPV31 are responsible 
for more than 90% of cases of cervical adenocarci-
noma [6].
HPVs are ubiquitary viruses and up to 80% of women 
acquire an infection during their lifetime, with the high-
est incidence in 20-40 year-olds [7, 8]. 
in most cases the infection clears and the mechanism of 
persistent infection is not triggered. However, HPV16, 
HPV18 and other oncogenic type infections tend to per-
sist more frequently than low-risk HPV infections. Per-
sistent oncogenic HPV infection represents the precur-
sor of invasive cervical cancer. Once the uterine cervix 
has been infected, low-grade squamous intraepithelial 
lesions can occur (aSCuS/LSiL, CiN1) which gener-
ally subside spontaneously. if they do not, high-grade 
squamous intraepithelial lesions can occur (HSiL, CiN2 
and CiN3), which are more likely to develop into inva-
sive cancer [9]. the time interval between the infection 
and the possible onset of cancer is 10-20 years [10].
it is estimated that 500,000 new cases of cervical can-
cer and about 270,000 deaths occur worldwide every 
year [6, 11, 12].
although not all the details are known, the immune 
response is known to play an important role, involving 
both humoral and cell-mediated immunity. Oncogenic 
HPVs are agents that can elude the host immune re-
sponse. this occurs because the virus is not cytolytic, 
does not cause inflammation, eludes recognition of the 
capsid antigens by Langerhans cells and inhibits type i 
interferons (alpha and beta).
Previous oncogenic HPV infections do not necessarily 
cause immunity to subsequent infections; the level of 
protection provided by natural infection varies and rein-
fections or new infections are possible.
it is believed that humoral immunity, mainly to L1, 
prevents the anchorage and entry of the virus into the 
cells; cell-mediated immunity is important in eliminat-
ing most natural infections [13-15].
On the basis of this knowledge, preventive vaccines 
have been developed with the objective of preventing 
HPV infection by induction of the humoral response 
(antibodies against L1). the development of preventive 
vaccines began after the demonstration that the expres-
sion of L1 capsid proteins in eukaryotic cells lead to 
the self-assembly in virus-like particles (VLPs). VLPs 
are similar in structure to HPVs, but do not contain any 
genetic material [16-18].
antibody-mediated immunity against L1 is type-spe-
cific and antibodies against L1 VLP protect against 
the infection and the disease. this fact was histori-
cally established by providing protection through the 
transfer of serum from vaccinated to non-vaccinated 
animals [19, 20].
as a result of the particular characteristics of HPVs, 
the level of antibody response that can be obtained by 
means of vaccination is higher than what is seen after 
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natural infection. Vaccination prevents infection by the 
induction of neutralizing antibodies that bind to sites 
present on the capsid and prevent infection of the host 
cell. the WHO believes that neutralizing antibodies are 
fundamental for post-vaccine protection against HPV 
infection even though there is no demonstration of 
either short or long-term immune correlate for protec-
tion [21, 22].
Modern technology makes it possible to modulate the 
quality and quantity of antigen-specific immune re-
sponse through the use of adjuvants [23, 24].
in the case of HPV infection it is important to elicit the 
production of high levels of serum neutralizing antibod-
ies by vaccination, since a certain amount of these must 
be available at cervical-vaginal level (by transudation 
or exudation) in order to prevent and block new infec-
tions [25].
On the basis of these scientific findings, two preventive 
vaccines for HPV were developed with the main objec-
tive of preventing the onset of cervical-vaginal cancer.
Since the two products were developed on the basis of 
different rationales and were evaluated in trials with 
different end-points, different structures and different 
laboratory methods, it is currently difficult to make 
a direct comparison of the results obtained with the 
two products. it is, however, possible to examine the 
scientific evidence acquired during the phase ii and iii 
studies for each vaccine, with particular reference to im-
munogenicity and clinical efficacy, protection duration, 
any cross-protection acquired, tolerability and safety.
as far as the evaluation of clinical efficacy is concerned, 
it should be pointed out that in addition to the “classic” 
clinical-histological end-points (CiN1, CiN2 and CiN3) 
it is important to consider the persistence of the infec-
tion as a key marker and to also therefore use virologi-
cal type assessments when examining the results of the 
clinical trials [26].
The bivalent vaccine
as a result of the first indications on the potential im-
pact of the L1 VLPs on cervical cancer, GSK developed 
a bivalent vaccine (Cervarix) containing HPV16 and 
HPV18 type L1 VLPs with the rationale of interven-
ing against the types responsible for around 70% of all 
cases of CiN2/3 and of cervical cancer and for around 
25% of all cases of CiN1. the L1 VLPs contained in 
the vaccine are produced by means of recombinant 
DNa technology using a baculovirus expression system 
in cells derived from Trichoplusia ni (Hi-5 Rix4446). 
the vaccine contains a new adjuvant system, named 
aS04, consisting of monophosphoryl lipid a (MPL), 
i.e. a detoxified lipopolysaccharide obtained from Sal-
monella minnesota adsorbed on aluminium hydroxide 
al(OH)3 [27]. the vaccine schedule foresees 3 doses to 
be administered at 0, 1 and 6 months; each dose contains 
20 μg of HPV16 L1 VLP, 20 μg of HPV18 L1 VLP, 50 
μg of aS04 and 0.5 mg of al3+. 
the use of the aS04 adjuvant system optimizes the 
immunological response; specifically, aS04 stimulates 
the antigen-presenting cells (aPC) through the toll-like 
receptors tLR-4. the stimulated dendritic cells (aPC) 
secrete cytokines and present L1 VLP antigens, optimiz-
ing the adaptive response, involving both b and t cells 
and causing the development of a clone of antigen-spe-
cific memory cells [28-30].
the potential of the aS04 adjuvant was previously 
evaluated for the development of an anti-HbV vac-
cine [31, 32] and then integrated in the anti-HPV16 and 
18 vaccine. this new adjuvant was also assessed with 
respect to the immune response induced with HPV16/18 
L1 VLPs in formulations containing only aluminium 
hydroxide. During a follow-up lasting up to 4 years, the 
aS04 adjuvant system was shown to induce an antibody 
response to HPV16/18 L1 VLPs in humans that was 
significantly higher and more persistent with respect 
to aluminium salts. in particular, these high antibody 
levels after the use of vaccine containing aS04 were 
confirmed by means of various methods, such as ELiSa 
(to determine total ab), pseudo-neutralization tests (for 
specific assessment of neutralizing ab) and inhibition 
ELiSa (to determine just epitope-specific ab) [33]. the 
same study also showed that one month after the third 
dose the frequency of the b memory cells specific for 
HPV16 L1 VLPs in the vaccinated subjects was sig-
nificantly higher than the one obtained with aluminium 
salts. a similar, albeit not significant trend was seen for 
HPV18 L1 VLPs.
the first efficacy study was performed by means of a 
double blind, randomized and controlled clinical trial 
in healthy women enrolled in brazil, Canada and the 
uSa [34]. the women were aged 15-25 years, had 
not had more than 6 sexual partners and did not have 
a positive history of abnormal PaP tests. all these 
women were also cytologically negative, seronegative 
for anti-HPV16 and anti-HPV18 antibodies (in ELiSa) 
and HPV-DNa-negative at PCR for 14 types of high-
risk HPV (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66 and 68). according to randomization, one 
group of women was vaccinated with three doses of 
bivalent vaccine (at 0, 1 and 6 months) while the second 
group received placebo (500 μg of aluminium hydrox-
ide/dose).
the study consisted of two stages: an initial stage with 
a post-vaccine follow-up of up to 18 months and a sec-
ond stage with an extended blind follow-up of up to 27 
months.
the primary objective of the study was evaluation of 
the vaccine’s efficacy in preventing HPV16 and HPV18 
infection at 6 and 18 months. the secondary end-points 
included: evaluation of the vaccine’s efficacy in pre-
venting persistent HPV16/18 infection and cytologically 
confirmed low-grade squamous intraepithelial lesions 
(LSiL), high-grade squamous intraepithelial lesions 
(HSiL) and CiN1, CiN2/3 lesions and HPV16/18-asso-
ciated carcinoma (squamocellular or adenocarcinoma) 
between months 6 and 18 and months 6 and 27. a total 
of 1,113 women were enrolled and randomized (560 
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received vaccine and 553 placebo). Compliance with the 
treatment was excellent (85.7% in the vaccine group and 
86.4% in the placebo group) and the drop-out rate was 
similar in the two groups.
as far as efficacy against incident infection is concerned, 
the vaccine was 100% effective against HPV16 and 
91.6% effective against HPV16/18 in the atP (accord-
ing to protocol) group. With regard to persistent infec-
tion, efficacy was 100% (for HPV16 and HPV16/18) in 
the atP group; for HPV18 statistical significance was 
reached in the itt (intention-to-treat) cohort (100%).
the efficacy in preventing abnormal cytology associ-
ated with HPV16/18 infection was 95.2%, 91.2% and 
92.9% respectively for HPV16, HPV18 and HPV16/18 
in the itt cohort.
in the atP group, the percentage of seroconversion af-
ter 3 doses (month 7) was 100% and 99.7% respectively 
for HPV16 and HPV18. at month 18 all the immunized 
women had seroconverted for both HPV16 and HPV18. 
the level of antibodies (expressed as geometric mean 
titre, GMt) was significantly higher at month 7 in the 
immunized women compared to the placebo group. in 
particular, the GMts the vaccinated women were over 
80-100 times higher than the antibody level detected 
in subjects with previous HPV16 and HPV18 natural 
infection. in vaccinated women the antibody levels were 
still high at month 18, being 10 to 16-fold higher than 
observed after natural infection.
as far as safety and tolerability are concerned, no seri-
ous adverse events were reported in either the vaccine 
or the placebo group. Local adverse reactions at the site 
of the vaccination were reported more frequently in the 
vaccinated women than in the placebo group. the local 
adverse reactions were, however, mild and short-lasting 
and did not reduce compliance to the treatment.
an extended follow-up study was also carried out in 
women enrolled in this trial and who had received three 
doses of vaccine or placebo and for whom double blind 
conditions continued (extended follow-up, multicentre, 
double blind, randomized and controlled study) [35]. 
the primary and secondary end-points were identical to 
the basic study. the extended follow-up, up to 4.5 years, 
included 776 women. More than 98% of the vaccinated 
women were persistently seropositive for anti-HPV16 
and HPV18 antibodies throughout the follow-up. the 
humoral response peaked a month after the third dose; 
the peak was followed by a slight decline of the GMt, 
reaching a plateau from month 18 onwards. at the end 
of the extended follow-up (months 51-53) the antibody 
level in the vaccinated women was around 17 and 14 
times higher, for HPV16 and HPV18 respectively, than 
post-infection levels detected in women with a previous 
natural infection. in the atP group, the efficacy of the 
vaccine against incident infection was 95.8%, 100% and 
96.9%, respectively for HPV16, HPV18 and HPV16/18. 
as regards persistent infection, the efficacy at 12 months 
was 100% against HPV16, HPV18 and HPV16/18. 
a combined analysis of the initial and follow-up stages 
showed the bivalent vaccine to be highly effective 
against HPV16/18-associated cytological abnormalities 
(aSCuS, LSiL) and 100% effective against HPV16/18-
associated histological abnormalities (CiN1 and CiN2) 
(no HPV18-associated lesions were detected). the vac-
cine was also found to be considerably effective with 
respect to the cytological and histological outcomes 
associated with any other high-risk HPV infection and 
regardless of the HPV DNa status. Efficacy against 
HPV45 and HPV31 incident infections was also re-
spectively found to be 94.2% and 54.5%. the level of 
tolerability and safety of the vaccine was excellent in 
this study too.
the women included in the extension of the phase ii 
trial continued their follow-up and the data at 6.4 years 
are now available. in particular, after that period the 
antibody levels reached after vaccination were still at 
least 11-fold higher than levels observed after natural 
infection. this was observed by determining the an-
tibody titre by means of both the ELiSa test and the 
pseudo-neutralization test. there is evidence that the 
ELiSa test used in these trials to detect the anti-HPV16 
and -HPV18 antibodies had, in all the age groups ex-
amined, a high degree of correlation with the levels 
detected with the pseudo-neutralization test, considered 
to be extremely reliable; this makes it possible to declare 
the ELiSa test an excellent surrogate for evaluating the 
response induced by the L1 VLPs [36].
it should be pointed out that an additional extension of 
the follow-up period is foreseen for the phase ii trial, 
taking it up to 9.5 years post-vaccination.
While the phase ii extended trial was reaching its final 
stages, a phase iii multicentre clinical trial began. this 
study, named PatRiCia, involved a very large popula-
tion (more than 18,000 women), aged between 15 and 
25 years and with less than 6 sexual partners. the crite-
ria for exclusion from the trial were limited to women 
with a positive history of colposcopy, women who were 
pregnant or breast-feeding at the time of the study, who 
had chronic or autoimmune diseases or were immunode-
ficient. unlike the previous studies, at the time of enrol-
ment some of the women were seronegative and DNa 
negative, seropositive and DNa negative, seronegative 
and DNa positive and seropositive and DNa positive 
for HPV16 or HPV18. this protocol made it possible 
to carry out a study that examined a population that was 
more similar to the general population, compared to the 
naïve population previously studied [37].
a total of 18,644 women were enrolled, 9,319 of whom 
were vaccinated with bivalent vaccine and 9,325 with 
HaV vaccine (control group). the primary end-point 
of the study was evaluation of the vaccine’s efficacy 
against CiN2+ associated with HPV16/18 in women 
who were initially seronegative and DNa negative for 
HPV 16 and 18. Secondary end-points were evaluation 
of the vaccine’s efficacy against CIN1 and CIN2+ as-
sociated with HPV16/18, against persistent infection (6 
and 12 months) for HPV16/18 or for other oncogenic 
HPV types (6 months), and of the immunogenicity and 
safety of the vaccine.
the protocol included a predefined intermediate evalu-
ation on reaching at least 23 cases of CiN2+ associated 
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with HPV16/18 DNa in the total vaccinated cohort 
(bivalent vaccine and control group) for efficacy. On 
the basis of these criteria, the efficacy of the vaccine 
against CiN2+ was 90.4%; efficacy against CiN1+ was 
89.2%. However, additional analyses made it possible 
to demonstrate that in the two cases detected in the 
vaccinated group and in the case of the control group it 
was not possible to identify HPV 16 or HPV18 in any 
previous cervical cytology sample, while other types of 
non-vaccine HPV had been identified in all the histo-
logical sections of the CiN2+ cases and in the previous 
cytological samples. based on these findings, a causal 
role of HPV 16 or HPV18 in the onset of the detected le-
sions was therefore excluded and the efficacy of the vac-
cine against CiN2+ for HPV16, HPV18 and HPV16/18 
became consequently equal to 100%.
as far as cross-protection is concerned, this was statisti-
cally significant against persistent infection at 6 months 
for HPV45 (59.9%) and HPV31 (36.1%), considered 
individually; a significant level of protection against 
persistent infection at 12 months was also detected for 
another 12 oncogenic HPV types considered, excluding 
HPV 16 and HPV18 (27.1%).
a total of 99.5% of the women who were seronegative 
at enrolment seroconverted both for HPV16 and HPV18 
after the second and third dose. at month 7 the antibody 
titres reached in the vaccinated group were significantly 
and consistently higher with respect to the levels de-
tected after natural infection.
as regards safety and tolerability, the data that emerged 
during the phase ii trials were confirmed; mild and 
short-lasting local adverse events at the inoculation site 
were recorded more frequently in the vaccinated group 
with respect to the control group.
the percentage of serious adverse events was marginal 
(0.1%), both in the vaccinated women and in the control 
group. there were no significant differences in pregnan-
cy outcomes in the overall study population (bivalent 
vaccine and control group).
another clinical trial evaluated the possibility of immu-
nising girls aged 10-14 years. in order to carry out this 
comparison, a total of 773 subjects were enrolled: 458 
aged 15-25 years and 158 aged 10-14 years. all subjects 
were immunised with three doses of bivalent vaccine at 
0, 1 and 6 months [38]. One month after the third dose, 
the seroconversion rate was 100% for both antigens in 
all subjects. the immunogenicity in the 10-14-year-old 
girls was not lower than the level found in the 15 to 25-
year-olds in terms of seroconversion. as regards the an-
tibody titres reached, the GMts in the girls aged 10-14 
years were substantially higher than those observed in 
the women aged 15-25 years and in the women enrolled 
in the first phase ii efficacy study.
the safety profile was similar in the two groups of 
subjects.
a study to evaluate the immunogenicity and safety of 
the bivalent vaccine in women aged between 26 and 55 
years is currently underway. the multicentre open study 
consists of two stages; the first with a follow-up at 1 
year after the first dose and the second with a follow-up 
extended up to 48 months. the results relative to the fol-
low-up at 24 months have already been published [39].
the objective of the study was to demonstrate that the 
seroconversion rates detected in women aged 26-45 and 
46-55 years are not lower than those in women aged 15-
25 years. the inclusion criteria consisted of a negative 
pregnancy test and the use of appropriate contraceptive 
measures. a total of 667 women were enrolled in the 
first stage of the study; it is worthy of note that at month 
24, 531 of these women were included in the extended 
follow-up period. Over 70% of the women evaluated 
in the atP cohort were seronegative for HPV16 and 
HPV18 at time 0. all the seronegative women, in both 
age groups, seroconverted for HPV16 and HPV18 one 
month after the third dose. the finding that the serocon-
version rates were not lower in the women aged 26-45 
and 46-55 years than in those aged 15-25 years was 
confirmed; the seroconversion rate was 100% in all the 
women. at month 24 all the women were still positive 
for anti-HPV16 and HPV18, regardless of age group.
the antibody response peak in terms of GMt was ob-
served at month 7 and the antibody kinetics were similar 
to what was observed in the phase ii and iii trials with 
a slight decrease at month 18, then reaching a plateau 
at month 24, in line with what was observed in women 
aged 15-25 years and in any case significantly higher 
than the antibody titres induced by natural infection. 
at month 24, the correlation between the serum anti-
body level and the level found in the cervicovaginal 
secretions was evaluated in a total of 250 women. the 
correlation coefficients were high, regardless of the age 
group considered. this finding merits careful evaluation 
since it is believed that the main mechanism of protec-
tion against HPV infections is mediated by the neutral-
izing antibodies, available at cervicovaginal level. the 
fact that, thanks to the action of the aS04 adjuvant, the 
bivalent vaccine induces a high antibody response also 
means a high level of antibodies available at the cervi-
covaginal level, where they can act effectively against 
HPV infections [25].
in this study too, the bivalent vaccine proved to be safe 
and well tolerated in all the age groups considered.
a further aspect worthy of note was the evaluation of 
the immunogenicity and safety of the bivalent vaccine 
in male subjects. a total of 270 healthy boys was en-
rolled, aged between 10 and 18 years, and vaccinated 
with HPV vaccine (3 doses) or HbV vaccine (3 doses). 
the exclusion criteria were a positive history of HPV or 
HbV vaccination, immunosuppression therapy in the 6 
months prior to the study or immunoglobulins or blood 
products in the 3 previous months, a clinical history 
of HbV infection, exposure to HbV in the 6 previous 
weeks and immunosuppression [40]. at month 2, 100% 
of the initially seronegative subjects presented antibodies 
against HPV16 and HPV18 and all subjects were serop-
ositive 1 month after completing the vaccination cycle.
the immune response in the boys aged 10-18 years was 
similar to that found in women aged 15-25 years. Local 
reactions, pain and swelling in particular, were more 
frequent in the subjects immunised with the bivalent 
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vaccine than in the control group, without however re-
ducing compliance with the treatment. 
Starting from the results of the first study on the efficacy 
of the bivalent vaccine, now at 6.4 years of observation, 
the long-term persistence of the antibody response to 
HPV16 and HPV18 infection was very recently esti-
mated [41].
these results were then analysed, applying 3 different 
statistical models (power-law and modified power-law) 
in order to obtain projections on the long-term duration 
of the antibody titres. it was seen that with all three 
models the levels of the antibodies against HPV16 and 
HPV18 remain significantly higher than those detected 
after natural infections for at least 20 years and, in the 
“most optimistic” model, for the entire lifespan. it is im-
portant to stress that these results were achieved without 
resorting to any recall dose which, in the prospect of a 
public health initiative, would have a negative impact in 
terms of organisation and costs.
Since a crucial point to be considered for the use of a 
vaccine is represented by its safety and tolerability, a 
group of researchers evaluated 11 different studies car-
ried out using the bivalent vaccine [42]. the analysis 
collected the data on safety from a cohort of around 
30,000 girls and women aged > 10 years, 16,142 of 
whom had received at least one dose of vaccine and 
13,811 at least one of the three control doses (alu-
minium hydroxide or HaV vaccine). the data avail-
able therefore related to over 45,900 doses; local and 
general adverse effects were recorded for 7 days after 
each dose. any serious adverse events, pregnancies, 
significant medical conditions and signs of new cases 
of chronic-degenerative disease, including autoimmune 
diseases, were also carefully monitored. the data were 
analysed by dividing them into age groups (10-14, 
15-25 and > 25 years) and time of reporting (0-7, 7-
12 and > 12 months). the data reported in this study 
were therefore taken from a large database and refer to 
subjects for whom the vaccination schedule and safety 
monitoring system were the same. the considerable 
size of the database also made it possible to evaluate the 
appearance of any rare adverse events. the bivalent vac-
cine demonstrated a favourable safety profile, similar to 
that of other licensed and commonly used vaccines. in 
particular, compliance with vaccination was high at all 
ages, the number of women who abandoned the trials 
due to adverse events or serious adverse events was low 
and not significantly different to the number recorded in 
the controls. the incidence of symptoms not specifically 
monitored was similar for all age groups in both the vac-
cinated and the control groups; there was no report of an 
increased risk of onset of chronic-degenerative diseases 
or of autoimmune diseases. No difference was detected 
in pregnancy outcomes between vaccinated and control 
subjects in any age group.
these data therefore demonstrate the favourable safety 
profile of the bivalent vaccine in women of all ages, 
confirming what was previously found by Verstraeten 
et al. [43], who evaluated the safety of vaccines con-
taining the aS04 adjuvant system, with particular at-
tention to adverse events with a potential autoimmune 
etiology.
The quadrivalent vaccine
the quadrivalent vaccine (Gardasil) was developed 
by Merck/Sanofi Pasteur MSD with the aim of acting 
against HPV16, HPV18, HPV6 and HPV11 and thus 
against 70% of all CiN2/3 infections and cases of cervi-
cal cancer, 90% of all genital warts and around 35-50% 
of all cases of CiN1. the vaccine schedule consists of 3 
doses to be administered at 0, 2 and 6 months. Each dose 
contains 40 μg of HPV16 L1 VLP, 20 μg of HPV18 
L1 VLP, 20 μg of HPV6 L1 VLP and 40 μg of HPV11 
L1 VLP adsorbed on adjuvant amorphous aluminium 
hydroxyphosphate sulfate (aaHS) (225 micrograms 
of al). the L1 VLPs are produced by means of recom-
binant DNa technology in S. cerevisiae.
as far as the adjuvant is concerned, aluminium salts 
have been historically used to potentiate the immune re-
sponse in many vaccines [44]. With respect to adjuvants 
consisting of aluminium phosphate (aLPO4) and alu-
minium hydroxide (aLOH), the amorphous aluminium 
hydroxyphosphate sulphate used in the quadrivalent 
vaccine makes it possible to optimize the quality and 
quantity of the immune response to the L1 VLPs. this 
was confirmed during animal model (mouse) experi-
ments, obtaining significantly higher antibody levels 
with respect to other aluminium salts; in particular, it is 
believed that aaHS allows a better uptake of L1 VLPs 
by the immune system than aluminium hydroxide [45]. 
the development of the quadrivalent vaccine has fol-
lowed the evaluation of the results obtained in the phase 
ii trial with a monovalent prototype vaccine containing 
40 μg of HPV16 L1 VLP [46]. this was a randomised, 
double-blind clinical trial, administering three doses of 
vaccine or placebo in non-pregnant women aged 16-23 
years, with a negative history for previous abnormal 
PaP tests and with not more than 5 sexual partners dur-
ing their lifetime.
the primary end-point was the evaluation of the effica-
cy against persistent HPV16 infection and the analysis 
involved women who were seronegative and HPV DNa 
negative (for HPV16) at the time of enrolment and HPV 
DNa negative at month 7.
Of the 2,392 women enrolled in the study, 1,194 re-
ceived the vaccine and 1,198 received placebo (contain-
ing 225 μg of adjuvant). the mean follow-up period 
was 17.4 months and the efficacy against persistent 
HPV16 infection was 100%. at month 7, the geometric 
mean titre (GMt) in the vaccinated group was higher 
than in the women who were seropositive at the time 
of enrolment (respectively 1,510 and 337 mMu/ml in 
competitive Ria). the vaccine was also well tolerated 
and no differences were observed in the incidence of 
adverse events between the vaccinated subjects and the 
placebo group.
a phase ii trial was subsequently carried out to define 
which of the three prepared formulations was better 
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in terms of safety, immunogenicity and efficacy [47]. 
the randomised, double-blind multicentre study used 
three different formulations of HPV16, HPV18, HPV6 
and HPV11 L1 VLPs while for the placebo 2 different 
doses of aluminium-based adjuvant (225 and 450 μg) 
were used. the different formulations of L1 VLPs were 
derived from the phase i trials previously carried out.
the study consisted of two stages: the first (stage a) 
evaluated the dose and was not completely blind. the 
second stage (b) was completely blind and the aim 
was to evaluate safety, efficacy and immunogenicity 
in relation to the dosage of L1 VLPs used. in stage b, 
1,106 healthy women were enrolled, aged 16-23 years, 
not pregnant, with a negative history for abnormal PaP 
tests and with less than 4 sexual partners during their 
lifetime. the study did not exclude the possibility of 
enrolling anti-HPV seropositive and/or HPV DNa posi-
tive women. the vaccine was administered at 0, 2 and 6 
months. an intermediate analysis of the data was carried 
out when around 50% of the post-dose 3 responses were 
available, with the aim of selecting the quadrivalent vac-
cine dose to be used in the phase iii studies.
at the time of the intermediate analysis, the anti-HPV 
GMt in the three immunised groups for each of the four 
vaccine components was higher (from 27 to 145 times) 
than the levels observed in the women treated with pla-
cebo and seropositive at enrolment. at month 7, the GMt 
reached for each of the 4 vaccine components was similar 
for the three formulations and 100% of the vaccinated 
women were seropositive. Determination of the antibod-
ies was carried out both by means of a competitive Ria 
method and a competitive Luminex immunoassay (cLia) 
which measures the neutralizing antibodies against spe-
cific conformational epitopes of the different HPV types 
(H6.M48 for HPV6, K11.b2 for HPV11, H16.V5 for 
HPV16 and H18.J4 for HPV18). On the basis of these 
data, the formulation with the lowest content of L1 VLPs 
(40 μg of HPV16 L1 VLP, 20 μg of HPV18 L1 VLP, 20 
μg of HPV6 L1 VLP and 40 μg of HPV11 L1 VLP) was 
chosen for use in the phase iii trials.
Considering the dose chosen for the phase iii trials, the 
antibody response was evaluated both in the randomised 
HPV-naïve women and in the women who were serop-
ositive and DNa negative at enrolment [48].
in general, the maximum antibody peak was reached one 
month after completing the vaccination cycle; this was 
followed by a decline in the antibody level until month 
18 when a plateau was reached, remaining stable for at 
least 2.5 years after administration of the third dose.
administration of the vaccine induced higher antibody 
levels in the seropositive women compared to those who 
were HPV-naïve at enrolment; this suggests the induc-
tion of a booster response in the seropositive women.
Evaluation of the long-term immunogenicity (month 36) 
demonstrated that the antibody levels induced with the 
vaccination against HPV18, HPV6 and HPV11 returned 
to the levels observed after natural infection; the anti-
HPV16 antibodies, on the other hand, remained around 
16 times higher compared to the levels observed after 
natural infection.
Evaluation of the long-term immunogenicity also 
involved establishing the number of subjects who se-
roconverted during the follow-up period. at month 7, 
100% of the HPV-naïve vaccinated women were se-
ropositive for all 4 vaccination components; at month 
18 and at month 36 the seropositivity levels were 
98%, 98%, 100% and 86%, and 94%, 96%, 100% and 
76% respectively for anti- HPV6, -HPV11, -HPV16 
and -HPV18 antibodies.
the vaccine proved to be safe and well tolerated. the 
number of subjects who reported any adverse event was 
slightly higher in the vaccinated group compared to the 
control group. the adverse events most frequently asso-
ciated with the vaccine were headache and fever; local 
adverse events (redness, pain and swelling) were also 
more frequently recorded in the vaccinated women than 
in the control group.
Evaluation of the immunogenicity carried out during the 
phase ii study reported above up to month 36 was subse-
quently extended up to month 60, involving 241 women 
and including determination in the vaccinated group of the 
antibodies against the vaccination components by means 
of the cLia test [49]. a number of the immunised women 
were found to be seronegative for one or more of the HPV 
vaccinal strains at month 60, confirming the downward 
trend of the antibody titre shown in the previous stage of 
the study. all the women included in the extended follow-
up period were immunised with an additional dose of vac-
cine at month 60 and the antibody response was evaluated 
one month later [50]. this dose induced an anamnestic 
response, making it possible to reach high antibody levels, 
in some cases higher than the levels observed at month 
7 after the administration of dose 3. this anamnestic re-
sponse was also observed in women who were seroposi-
tive and PCR negative at enrolment, and then immunised 
with three doses of the vaccine.
During the phase ii study, the characteristics of which 
have already been described, the vaccine efficacy was 
also evaluated [49]. a first assessment was performed 
during the follow-up period at 36 months, showing vac-
cine efficacy against the incidence of HPV6, HPV11, 
HPV16 and HPV18 infection or cervical or external 
genital disease (persistent infection, detection of HPV 
at the last examination, CiN, carcinoma, external genital 
lesions sustained by HPV types present in the vaccine). 
Overall efficacy was 90%.
the extended follow-up in the women enrolled in this 
study demonstrated 95.8% efficacy against infection 
or disease in the atP cohort (which included both the 
women initially enrolled for the study with a 3-year 
follow-up and those included in the extended 5-year fol-
low-up) and 95.1% efficacy in the atP cohort limited to 
the women in the extended follow-up period.
in the Mitt (modified intention to treat) cohort, which 
included subjects who were HPV-naïve for HPV6, 
HPV11, HPV16 and HPV18 treated with at least one 
dose, regardless of any protocol infringements, efficacy 
was 93.7%.
in 2006, the results were published of a study aimed at 
determining whether the antibody response induced by 
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L1 VLPs in subjects aged 10-15 years was comparable 
with what had been observed in women aged 16-23 
years. this was therefore a bridging immunogenicity 
study, its rationale being based on the legal and ethical 
impossibility of evaluating the clinical efficacy of the 
vaccine in preadolescents and adolescents [51]. the 
multicentre study involved the enrolment of 3 groups 
of subjects: males aged 10-15 years, females aged 10-
15 years and females aged 16-23 years. the first two 
groups had to be healthy subjects who had not started 
sexual activity and did not do so during the study; the 
older subjects had to have a negative history for abnor-
mal PaP tests, genital warts or CiN and not have had 
more than 4 sexual partners. a negative pregnancy test 
was required for all the women/girls. the three doses of 
vaccine were administered at 0, 2 and 6 months. immu-
nogenicity was evaluated by means of cLia.
a total of 1,529 subjects were enrolled, 94.8% of whom 
completed the immunisation protocol. Evaluation of the 
anti-HPV GMts at month 7 in the HPV-naïve subjects 
showed that the results obtained in the 10-15 year-olds 
were not lower with respect to the levels observed in the 
16-23 year-olds. the GMts observed in the males and 
the younger females after dose 3 were consistently high-
er than in the women aged 16-23 years. More than 99% 
of the enrolled subjects had seroconverted at month 7. 
the vaccination was also safe and well tolerated in all 
the groups of subjects included in the study.
From June 2002 to May 2003 a phase iii, multicentre, 
double-blind, randomised, controlled study (FutuRE 
ii) was performed in women aged 16-26 years. the 
women were eligible for the study if they were not preg-
nant, had a negative history for abnormal PaP tests and 
had not had more than 6 sexual partners. the women 
were treated with vaccine (3 doses at 0, 2 and 6 months) 
or with placebo (containing aluminium). a total of 
12,167 women were enrolled, 6,087 of whom received 
the vaccine. the results were published in two separate 
articles in 2007.
in the first publication, the primary end-point was 
evaluation of the efficacy of the vaccine against high-
grade CiN for HPV16 and HPV18 [52]. the vacci-
nated women were followed for a mean period of three 
years after administration of the first dose of vaccine 
or placebo. the intermediate evaluation of the study 
was based on identification of at least 19 cases of 
high-grade CiN while the final analysis required iden-
tification of at least 29 cases. in the per protocol cohort 
(women serologically HPV16 and HPV18 DNa nega-
tive at enrolment and HPV16 and HPV18 DNa nega-
tive up to month 7) vaccine efficacy was 98% against 
high-grade HPV16 or HPV18 lesions (CiN2-3). the 
only vaccinated subject presenting a case of HPV16 
CiN3 was positive for HPV52 both at enrolment and 
in another 5 histological samples taken during the fol-
low-up period; HPV16 DNa was, on the other hand, 
detected only in one histological sample. in the unre-
stricted cohort, which included seronegative women 
with negative PCR at enrolment, vaccine efficacy for 
the same end-points was 95%. Evaluation of vaccine 
efficacy against high-grade HPV16 or HPV18-related 
lesions in a population that included women with and 
without infection or CiN at enrolment and treated with 
at least 1 dose was performed in the intention-to-treat 
cohort. in this case, efficacy against high-grade HPV16 
and HPV18-related lesions was 44%. Considering the 
appearance of any HPV type high-grade lesions, vac-
cine efficacy was 17%.
in the same study, a group of 1,512 women were in-
cluded in an immunogenicity evaluation; at month 24 
the seropositive rate for neutralizing antibodies in the 
protocol cohort was 96%, 97%, 99% and 68% respec-
tively for HPV6, HPV11, HPV16 and HPV18.
the vaccine presented an excellent safety and tolerabil-
ity profile; no significant differences were observed in 
the outcome of pregnancies occurring in the vaccinated 
women or in those treated with placebo.
the second published article reported the data relative 
to two end-points: reduction with respect to the placebo 
group of the incidence of anogenital warts, grade 1-3 
vulvar or vaginal lesions or neoplasia associated with 
any type of HPV and reduction with respect to the 
placebo group of the combined incidence of CiN1-3, 
adenocarcinoma in situ or carcinoma associated with 
the HPV types included in the vaccine [53]. identifica-
tion of 38 cases of anogenital or vaginal lesions and at 
least 38 cases of cervical lesions associated with the 
HPV types included in the vaccine were required to 
ensure the power of the study. an intermediate analysis 
was performed when 38 cases of anogenital and vaginal 
lesions and 37 cases of cervical lesions had occurred at 
around 1.5 years after administration of the third dose. 
Evaluation of the efficacy was carried out considering 
the per protocol, unrestricted and intention-to-treat co-
horts described above.
a total of 2,723 women were vaccinated and 2,732 re-
ceived placebo; the mean follow-up period was 3 years 
after administration of dose 1.
in the per protocol cohort, immunisation proved 100% 
effective in preventing vaginal, vulval, perineal or peri-
anal lesions or warts in association with vaccine-type 
HPV; efficacy against CiN1-3 lesions caused by HPV 
types included in the vaccine was also 100%.
in the unrestricted cohort, the combined efficacy against 
any type of external anogenital or vaginal lesions and 
against cervical lesions of any grade was, respectively, 
95% and 98%.
Finally, in the intention-to-treat group, efficacy against 
any external anogenital or vaginal lesions and against 
cervical lesions of any grade was 73% and 55%.
a second analysis of the intention-to-treat cohort was 
performed to evaluate the vaccine efficacy regardless 
of the type of HPV involved (whether included in the 
vaccine or not); efficacy against the incidence of exter-
nal anogenital or vaginal lesions and against cervical 
lesions was, respectively, 34% and 20%.
at least 99.5% of the women included in the per proto-
col cohort had seroconverted at month 7. the safety and 
tolerability profile was confirmed as satisfactory. Local 
adverse events at the inoculation site and fever were 
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reported more frequently among the vaccinated women 
than in the control groups (87% vs 77% and 13.3% vs 
10.3%).
in 2007, two studies were published, one on the com-
bined analysis of 4 clinical trials on the efficacy of the 
quadrivalent vaccine against CiN2-3 lesions and adeno-
carcinoma in situ and the other on the combined analysis 
of 3 clinical studies on the vaccine efficacy against high-
grade vulval and vaginal lesions.
the first combined analysis evaluated over 20,000 
women aged 16-26 years, randomised to receive the 
quadrivalent vaccine, the monovalent HPV16 vaccine or 
placebo [54]. the primary end-point was evaluation of 
the combined efficacy against CiN2-3, aiS or cervical 
cancer caused by HPV16/18. after a mean follow-up 
period of three years after the first dose, vaccine ef-
ficacy in HPV-naïve women was 99%; in the intention-
to-treat cohort it was 44%. a second intention-to-treat 
analysis showed an 18% reduction of CiN2-3 or aiS 
regardless of the type of HPV considered.
the second combined analysis involved over 18,000 
women (16-26 years) randomised to receive quadri-
valent vaccine or placebo [55]. the primary end-point 
was evaluation of the combined efficacy for ViN2-3 or 
VaiN2-3 caused by HPV16 or HPV18.
after three administrations and a mean follow-up period 
of 3 years, efficacy against ViN2-3 and VaiN2-3 was 
100% in the HPV16 and HPV18 naïve women (per pro-
tocol cohort) and 71% in the intention-to-treat cohort; 
efficacy against ViN2-3 and VaiN2-3, regardless of 
the type of HPV considered, was found to be 49%. the 
quadrivalent vaccine was found to be safe and effective 
in this study too. 
a clinical trial carried out within the phase iii study de-
scribed above evaluated the safety and immunogenicity 
of co-administered quadrivalent vaccine and HbV vac-
cine [56]. the trial involved 1,877 women, aged 16-23 
years, and demonstrated that co-administration induced 
high GMt levels against the various HPV vaccine 
components and a seroconversion rate ( > 99%) that 
was not lower than could be achieved by administer-
ing the quadrivalent vaccine alone. as far as the HbV 
vaccination was concerned, high antibody titres were 
observed at month 7, albeit lower on the whole than 
those achieved with the HbV vaccination alone. the 
co-administration was generally well tolerated.
two reviews were very recently published on the im-
pact of the quadrivalent vaccine on infection and disease 
associated with oncogenic non-vaccine HPV types in 
HPV-naïve women aged 16-26 years.
the first review refers to 17,622 enrolled women 
with a mean follow-up of 3.6 years [57]; the primary 
end-point was verification of the prevention of the 
combined incidence of HPV31, HPV45 and HPV-
31/33/45/52/58-related infections and disease. Other 
end-points were verification of the prevention of the 
combined incidence of infections and disease related 
to non-vaccine HPV types (HPV31, 33, 35, 52, 58, 39, 
45, 59, 51, 56). the analysis was carried out in women 
who had received > 1 dose and who were seronegative 
and HPV DNa negative for the HPV types included in 
the vaccine, DNa negative for each of the 10 non-vac-
cine HPVs indicated above and who had a normal PaP 
test at enrolment.
Efficacy (evaluated in 2,068 women) was 40.3% and 
25% respectively against the incidence of HPV31/45 
and HPV-31/33/45/52/58 infection; the analysis per-
formed to evaluate efficacy against each individual type 
of HPV investigated was statistically significant only 
for HPV31 (46.2%).
the analysis of 9,296 subjects to evaluate the effi-
cacy against cervical disease showed values of 23.4% 
and 32.5%, respectively, against CiN1-3/aiS and for 
high-grade lesions (CiN2-3/aiS) against 10 non-vac-
cine HPV types. the efficacy against the incidence of 
CiN1-3/aiS caused by HPV31/45 was 43.6% while the 
efficacy against the incidence of CiN1-3/aiS correlated 
with HPV-31/33/45/52/58 was 29.2%. in general, a sig-
nificant level of efficacy against infection and disease 
caused by HPV45 was not demonstrated.
the second review reports the data on the evaluation 
of quadrivalent vaccine efficacy on the incidence of 
persistent infection (> 6 months) or on cervical disease 
due to HPV31 and HPV45 and to HPV31/33/45/52/58 
in an intention-to-treat cohort [58]. Other end-points 
included evaluation of the efficacy against persistent in-
fection (> 6 months) or disease associated with species 
a9 (HPV31, 33, 52, 58) and a7 HPV types (39, 45, 59) 
and with all non-vaccine HPV types that can be tested 
(HPV31, 33, 35, 39, 45, 51, 52, 58, 59). the women 
(16-26 years and enrolled for the phase iii studies) were 
included in the analysis regardless of the presence of 
HPV infection or HPV-correlated disease at enrolment; 
the mean follow-up was 3.6 years after administration 
of dose 1.
the quadrivalent vaccine reduced the incidence 
of persistent HPV31/45 infection by 31.6% and of 
HPV31/33/45/52/58 infection by 17.7%. a significant 
level of efficacy against the incidence of persistent in-
fection was observed for HPV31 (33.6%) and HPV59 
(24.6%).
With regard to efficacy against HPV-related dis-
ease, the quadrivalent vaccine reduced the incidence 
of HPV31/45-related CiN1-3/aiS by 22.2% and of 
HPV31/33/45/52/58-related CiN1-3/aiS by 18.8%. the 
combined efficacy for the 10 non-vaccine HPV types 
against CiN1-3/aiS was 15.1%; a significant level of 
efficacy was observed against HPV31, HPV58 and 
HPV59-related CiN1-3/aiS (26%, 28.1%, 37.6% re-
spectively).
the ECDC Newsletters on vaccines and immunization 
recently published a comment on these last two studies 
pointing out: “in summary, the potential of cross-protec-
tion was very small if all women were included regard-
less of status of infection or disease at enrolment [58]. 
the modest reduction of CiN2 lesions or worse was not 
statistically significant. as expected, the efficacy of the 
vaccine against HPV infection and HPV related disease 
was much higher in the group of women that were 
HPV negative at study entry, and the predominant non-
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vaccine type was HPV31. both here-presented studies 
used the study population recruited for the Future i 
and ii studies, which were designed to estimate the 
impact of the quadrivalent vaccine on CiN1-3 and aiS 
associated with the HPV types included in the vaccine. 
around 70% of cervical cancer cases as well as the 
majority of cervical high-grade lesions are associated 
with HPV types 16 and 18. therefore both studies were 
probably underpowered to estimate the vaccine impact 
on disease associated with nonvaccine HPV types, and 
the results have to be interpreted carefully. Even if 
both studies may contribute to the answer, the ques-
tion of possible cross-protection remains unsolved, and 
should be looked at further as it plays an important role 
in estimating the effectiveness and impact of available 
measures including vaccination for the prevention of 
cervical cancer …” [59].
as far as evaluation of long-term immunogenicity is 
concerned, the application of two different mathemati-
cal models using the antibody levels detected two years 
after the administration of the monovalent vaccine 
containing HPV16 L1 VLPs produced different indica-
tions [60]. the conventional mathematical model indi-
cates that the anti-HPV16 antibodies decrease in < 20 
years below the antibody level reached after natural 
infection. the modified model, which presumes a long-
term immune memory, indicates instead that the anti-
HPV16 antibodies are persistently high, above the level 
detected after natural infection.
as far as safety and tolerability are concerned, the quad-
rivalent vaccine was well tolerated with a favourable 
safety profile [61, 62]. the most frequent adverse events 
were fever, erythema, pain, swelling and itching at the 
inoculation site. administration of the quadrivalent vac-
cine during pregnancy did not lead to any reports; nev-
ertheless, the data currently available are not sufficient 
to recommend use of the vaccine during pregnancy. 
During the clinical studies, the subjects included in the 
safety analysis reported any new clinical condition that 
occurred during the follow-up.
according to the CDC the overall evaluation of more 
than 20 million doses passively monitored and more 
than 375,000 doses actively monitored demonstrated a 
number of reports that were coherent with the results 
of the clinical trials [62]. the data available do not 
support the causal association between the vaccine and 
Guillain barré syndrome or venous thromboembolism 
nor any evidence of a high risk of syncope after admin-
istration of the vaccine, except in adolescents. the data 
available in the uSa do not support the preliminary 
indications reported in australia on some cases of de-
myelinising disease or post-vaccination anaphylaxis.
Concluding remarks
Evaluation of the data emerging from the numerous 
clinical trials carried out on the two HPV vaccines con-
firms the high preventive value of vaccination.
While not directly comparable, the data obtained with the 
two available vaccines indicate that the immune response 
can be effectively modulated in terms of quality and 
quantity as well as duration by using different adjuvants 
which make it possible to maximise the immune action.
We are therefore waiting for a direct comparison be-
tween the two products, based on homogeneous popu-
lations, with the same end-points and performed using 
unambiguous laboratory methods, in order to show the 
existence of “real” differences regarding the activity of 
the two vaccines currently available. 
Despite considerable and confirmed clinical efficacy 
and established tolerability and safety, there are some 
aspects that still require further investigation:
• significance of the immune response and identifica-
tion of a protective serological correlate;
• duration of the protection;
• cross-protection;
• the possibility of co-administration with other vaccines; 
• update of the cost-efficacy profiles;
• long-term impact of the vaccination on the ecology 
of HPVs.
the WHO has very recently published a position paper 
on HPV vaccination, recommending that this vaccina-
tion be included in the immunisations programmes of 
countries in which the prevention of cervical cancer 
represents a priority in terms of public health. this 
intervention must be sustainable from an organisational 
and economic point of view, and in-depth cost-efficacy 
studies are therefore necessary. Since the HPV vaccines 
currently available are highly effective in girls who are 
naïve for the vaccine HPV types, the primary target 
of immunization programmes should be girls aged be-
tween 9-10 and 13 years. the vaccination programmes 
should also be included in a coordinated strategy of 
health education (on behaviour at risk for HPV infec-
tion) and information on the need for integration with 
cervical cancer screening programmes [63].
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